» Articles » PMID: 39022984

Oligomerization of Protein Arginine Methyltransferase 1 and Its Effect on Methyltransferase Activity and Substrate Specificity

Overview
Journal Protein Sci
Specialty Biochemistry
Date 2024 Jul 18
PMID 39022984
Authors
Affiliations
Soon will be listed here.
Abstract

Proper protein arginine methylation by protein arginine methyltransferase 1 (PRMT1) is critical for maintaining cellular health, while dysregulation is often associated with disease. How the activity of PRMT1 is regulated is therefore paramount, but is not clearly understood. Several studies have observed higher order oligomeric species of PRMT1, but it is unclear if these exist at physiological concentrations and there is confusion in the literature about how oligomerization affects activity. We therefore sought to determine which oligomeric species of PRMT1 are physiologically relevant, and quantitatively correlate activity with specific oligomer forms. Through quantitative western blotting, we determined that concentrations of PRMT1 available in a variety of human cell lines are in the sub-micromolar to low micromolar range. Isothermal spectral shift binding data were modeled to a monomer/dimer/tetramer equilibrium with an EC for tetramer dissociation of ~20 nM. A combination of sedimentation velocity and Native polyacrylamide gel electrophoresis experiments directly confirmed that the major oligomeric species of PRMT1 at physiological concentrations would be dimers and tetramers. Surprisingly, the methyltransferase activity of a dimeric PRMT1 variant is similar to wild type, tetrameric PRMT1 with some purified substrates, but dimer and tetramer forms of PRMT1 show differences in catalytic efficiencies and substrate specificity for other substrates. Our results define an oligomerization paradigm for PRMT1, show that the biophysical characteristics of PRMT1 are poised to support a monomer/dimer/tetramer equilibrium in vivo, and suggest that the oligomeric state of PRMT1 could be used to regulate substrate specificity.

Citing Articles

Hetero-oligomeric interaction as a new regulatory mechanism for protein arginine methyltransferases.

Bae A, Zheng Y Biochem Soc Trans. 2024; 52(5):2193-2201.

PMID: 39324605 PMC: 11624628. DOI: 10.1042/BST20240242.


Oligomerization of protein arginine methyltransferase 1 and its effect on methyltransferase activity and substrate specificity.

Rossi V, Nielson S, Ortolano A, Lonardo I, Haroldsen E, Comer D Protein Sci. 2024; 33(8):e5118.

PMID: 39022984 PMC: 11255602. DOI: 10.1002/pro.5118.

References
1.
Hevel J, Price O . Rapid and direct measurement of methyltransferase activity in about 30 min. Methods. 2019; 175:3-9. DOI: 10.1016/j.ymeth.2019.10.002. View

2.
Dong J, Duan J, Hui Z, Garrido C, Deng Z, Xie T . An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022). Expert Opin Ther Pat. 2023; 32(12):1185-1205. DOI: 10.1080/13543776.2022.2163162. View

3.
He L, Hu Z, Sun Y, Zhang M, Zhu H, Jiang L . PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells. DNA Repair (Amst). 2020; 95:102953. DOI: 10.1016/j.dnarep.2020.102953. View

4.
Morales Y, Nitzel D, Price O, Gui S, Li J, Qu J . Redox Control of Protein Arginine Methyltransferase 1 (PRMT1) Activity. J Biol Chem. 2015; 290(24):14915-26. PMC: 4463439. DOI: 10.1074/jbc.M115.651380. View

5.
Chen Y, Liang W, Du J, Ma J, Liang R, Tao M . PRMT6 functionally associates with PRMT5 to promote colorectal cancer progression through epigenetically repressing the expression of CDKN2B and CCNG1. Exp Cell Res. 2022; 422(1):113413. DOI: 10.1016/j.yexcr.2022.113413. View